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Abstract 34 
Primary aldosteronism (PA) is the most common endocrine cause of resistant hypertension. 35 
Individuals with PA are at increased cardiovascular risk, and an appropriate management 36 
and treatment would ideally reduce such risk. Screening and diagnosis of PA requires specific 37 
diagnostic test, it is considered as a time- and cost-consuming and, as a result, it is 38 
underperformed in clinical practice. An online survey reviewing available diagnostic 39 
procedures, laboratory testing and clinical protocols for screening and confirmation of PA 40 
diagnosis was conducted among clinical lead of Excellence centers of the Italian 41 
Hypertension Society.  42 
A total of 102 questionnaires were sent and 62 centers participated to the survey. The 43 
assessment of the plasma renin (plasma renin activity/direct renin concentration) and 44 
plasma aldosterone concentration (PAC) were available among all centers. Captopril 45 
challenge test (CCT) and saline infusion test (SIT) were available in the 60% and 61% of 46 
centers, respectively. Fludrocortisone suppression test was available in the 32% of the units. 47 
Adrenal vein sampling was accessible at the 32% of the centers. We found discrepancies in 48 
cut-off levels of aldosterone-to-renin ratio (ARR), and PAC after SIT. Other discrepancies 49 
involved the duration of the wash-out period before ARR testing, and dosage of captopril 50 
administered during CCT. 51 
In conclusion, although all centers are sufficiently equipped to perform PA screening, often 52 
patients should be referred to other centers to confirm the diagnosis of PA. A greater 53 
uniformity across centers to define precise cut-offs for screening and confirmatory testing 54 
for the diagnosis of PA would be of utility. 55 
  56 
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Summary table 57 
 58 
What is known about topic 59 
1. Screening and diagnosis of primary aldosteronism is usually underperformed by 60 
general practitioners, because of excessive time consumption, technical difficulties, 61 
and potential harm related to some procedures. 62 
2. The evaluation of primary aldosteronism performed among Hypertension Reference 63 
Centers would ideally ensure an optimal allocation of resources, in view of the fact 64 
that most of the centers are equipped with dedicated medical staff and appropriate 65 
diagnostic techniques. 66 
 67 
What this study adds 68 
1. The present research demonstrated that, among Italian Excellence and Reference 69 
Centers, there is large availability of screening and confirmation test for the diagnosis 70 
of primary aldosteronism. 71 
2. However, we found a rather heterogeneous behavior across Centers in terms of 72 
methodologies, protocols and cut-off values related to diagnostic work-up for PA, 73 
suggesting that a greater uniformity across centers to confirm/exclude PA is highly 74 
desirable. 75 
3. Finally, some technically-demanding and costly procedures, such as lateralization 76 
procedures requiring adrenal venous sampling and genetic testing, are available in 77 
only a small minority of the centers, suggesting the need to create a national network 78 
to facilitate the access to these procedures. 79 
  80 
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Introduction 81 
Arterial hypertension, defined as systolic blood pressure (SBP) ≥140 mmHg or diastolic blood 82 
pressure (DBP) ≥90 mmHg, is a major public health concern [1]. Despite increased 83 
awareness, the estimated rate of annual cardiovascular (CV) and all-cause deaths associated 84 
with arterial hypertension is on the rise [2]. This finding could be, in part, attributable to the 85 
increased burden of resistant hypertension (RH), defined as the failure of anti-hypertensive 86 
drug treatment with at least 3 drugs to obtain adequate BP control [3]. RH is frequently 87 
sustained by the presence of secondary causes, which require specific diagnostic testing 88 
and management.  89 
Primary aldosteronism (PA), defined as the autonomous overproduction of aldosterone, 90 
inappropriate for sodium status, is the most common endocrine cause of arterial 91 
hypertension. Recent studies have described the true prevalence of PA to vary between 5% 92 
and 10% of all cases of arterial hypertension [4-6], with even higher rates of prevalence 93 
among subjects with RH [7]. As compared with individuals with essential hypertension, 94 
subjects with PA display higher rates of target organ damage [8-12] and CV events for 95 
similar BP values [13-17]. Therefore, the prompt diagnosis of PA and the identification of its 96 
subtypes is of outmost importance, not only to address affected patients to the appropriate 97 
management, but also to potentially revert this risk excess [15-17]. 98 
The Endocrine Society Clinical Practice Guideline recommends case detection of PA in certain 99 
patient subgroups with: BP >150/100 mmHg or RH, hypertension and spontaneous or 100 
diuretic-induced hypokalemia, hypertension and adrenal incidentaloma, hypertension and 101 
obstructive sleep apnoea, hypertension and a family history of early onset hypertension or 102 
cerebrovascular accident at a young age, and all hypertensive first-degree relatives of 103 
patients with PA [18]. These would cover nearly 50% of all hypertensive subjects. However, 104 
screening and diagnosing PA, in particular in the general practitioner setting, is often 105 
considered as time-consuming, cumbersome, and in some cases potentially harmful (e.g. 106 
due to wash-out of some anti-hypertensive drugs, salt-loading protocols and invasive 107 
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examinations). As a result, screening and diagnosis of PA by general practitioners is often 108 
largely underperformed [19]. 109 
The Italian Hypertension Society (Società Italiana dell’Ipertensione Arteriosa, SIIA) 110 
promotes a network of Italian Excellence and Reference Centers for the diagnosis and 111 
treatment of arterial hypertension, where hypertensive patients are usually referred by 112 
general practitioners for a second-level assessment. This network ensures an optimal 113 
allocation of health resources for an accurate diagnosis of PA. In fact, most of the centers 114 
do have availability of dedicated medical staff, advanced diagnostic techniques and the 115 
expertise to perform a comprehensive assessment of secondary forms of hypertension [20]. 116 
The current article presents the results of a National survey conducted among SIIA Italian 117 
Hypertension Centers, with the aim of reviewing the current available diagnostic procedures, 118 
laboratory testing and clinical protocols for screening and diagnosis of PA. 119 
 120 
 121 
Methods 122 
The survey was conducted between August and November 2016. An online questionnaire, 123 
drafted by the Young Investigator Group of the SIIA under the supervision of the SIIA 124 
Executive Committee, was sent to the clinical lead of Reference and Excellence centers of 125 
the SIIA. Those who gave explicit consent to participate, received a link with the electronic 126 
form, and were invited to fill the online questionnaire anonymously. The questionnaire was 127 
easy to fill in and the average time to complete it was around 15 minutes. The questionnaire 128 
included 12 items exploring the availability and accessibility of technologies, methodologies 129 
and related procedures, usually adopted to screen and confirm the diagnosis of PA in 130 
hypertensive outpatients (first wave). Non-responders were invited to participate two more 131 
times with repeated online invitations. Those who did not respond to any of the three 132 
invitations were excluded from the study. Reasons for not responding were not assessed.  133 
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In brief: the questionnaire included three questions to understand the list of laboratory 134 
exams, functional test and instrumental settings available within each center. Question 4 135 
and 5 evaluated some aspects related to the methodology for PA screening. Two questions 136 
investigated the diagnostic cut-off values adopted by each center for the aldosterone-to-137 
renin ratio (ARR) and plasma aldosterone levels after intravenous saline infusion test (SIT). 138 
Question 8 explored the drug dosage commonly used in captopril challenge test (CCT). 139 
Question 9 investigated the instrumental diagnostic for the evaluation of the morphology of 140 
the adrenal gland. Finally, questions 10 to 12 were related to the screening for obstructive 141 
sleep apnea syndrome (OSAS) in subjects with PA, the use of ABPM as a tool for the 142 
diagnosis of secondary hypertension, and the accessibility of each single center to genetic 143 
testing facilities. To better elucidate some aspects of the questionnaire, responders were 144 
subsequently invited to provide further details by filling a further list of brief questions 145 
(second wave) related to: details of drug withdrawal before screening test for PA, indications 146 
to fludrocortisone suppression test (FST) and dexamethasone suppression test, body 147 
position during SIT, availability at the center and success rate of adrenal vein sampling 148 
(AVS). 149 
 150 
 151 
Results 152 
The questionnaire was sent to 102 Hypertension Centers, and a total of 62 fully-filled 153 
questionnaires were collected, both including the first and second wave, giving an overall 154 
response rate of 61%. Responders were well distributed among the three Italian macro-155 
regions (North n=30, 48%; Centre n=15, 24%, and South n=17, 28%). 156 
Table 1 reported a list of the main diagnostic test and procedures for PA screening and 157 
diagnosis, and the number of excellence and reference centers where each test is available, 158 
divided by macro-regions. The assessment of the plasma renin activity (PRA) or direct renin 159 
concentration (DRC) plus plasma aldosterone concentration (PAC) was available among all 160 
centers (100%). Second-level functional tests to confirm/exclude the suspect of PA are 161 
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available in the 82% of the units (at least one available test in 51 out of 62 centers). 162 
Specifically, CCT and SIT are technically available at the 60% and 61% of centers, 163 
respectively, whereas the fludrocortisone suppression test (FST) is available at the 32% of 164 
the units. This test is routinely performed only in the 20% of these units (n=4), whereas in 165 
the majority of the cases (55%) the test is performed only in the presence of contrasting 166 
results from other confirmatory tests. In five units, although technically available, the test 167 
is usually not performed.  168 
Dedicated staff and diagnostic resources to perform selective catheterization of adrenal 169 
veins (AVS) were available at 20 centers (32%, North=10, Center=6, South=4). However, 170 
only in half of the cases (n=10) the test is performed at the center, whereas in the remaining 171 
cases (n=10), although the procedure is technically available, the patients is usually referred 172 
to another center. Interestingly, in 5 centers (8%), the surgical treatment of lateralized PA 173 
is based only upon laboratory and imaging results. The overall approximate success rate in 174 
those centers where the procedure is usually performed (n=10) is >80% in 8 out of 10 175 
centers, 60-70% in 1 center, and below 60% in the remaining center. 176 
We found that in more than half of the centers (N=34, 55%), ARR was calculated by 177 
considering PRA, whereas in 27 units (45%) through the assessment of direct renin 178 
concentration (DRC). The evaluation of 24-h sodium and potassium urinary concentrations 179 
was systematically requested to all subjects screened for PA only by 27 centers (44%) whilst 180 
in the majority of the units (56%, n=35), this exam was performed only in selected cases. 181 
The discontinuation from drugs interfering with the renin-angiotensin-aldosterone system 182 
(e.g. β-blockers, ACE-inhibitors, angiotensin receptor blockers, diuretics, with the exception 183 
of alpha-blockers and calcium channel blockers) before plasma renin assay is variably 184 
performed among units, being always performed in rather 2/3 of the centers (n=40, 65%); 185 
in other cases, drugs with minor effects on the RAA system are maintained and results are 186 
interpreted by taking into account the effects of concomitant treatment on PRA/DRC and 187 
PAC levels (n=18, 29%). In 6% of the cases (n=4) the wash-out of interfering drugs is 188 
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usually not performed. The average duration of wash-out period is rather variable among 189 
units, being ≥15 days for 44 centers (71%), 3-4 days for 23% of the units (n=14). 190 
The cut-off value of ARR suggesting the presence of PA was set at 30 (with PAC in ng/dL 191 
and PRA in ng/mL/h) / 2.7 (with PAC in ng/dL and DRC in mU/L) in 56% of the centers 192 
(n=35), at 40/4.9 in the 40% (n=25), and at 20/2.4 in only 4% of centers (n=2, Figure 1). 193 
The diagnostic cut-off level of serum aldosterone adopted to confirm the diagnosis of PA 194 
after SIT also showed heterogeneity among centers: it was 10 ng/dL in 47% of centers, 7.5 195 
ng/dL in 24% of centers, and 5 ng/dL in 29% of the centers (Figure 2). Another discrepancy 196 
between centers is related to body position during SIT test: in 15 centers (39%) it is 197 
performed in seated position, whereas in 23 centers (61%) in supine position. Also drug 198 
dosage administered for CCT was relatively variable among centers: 50 mg was the dosage 199 
adopted in the 77% of the centers, while the remaining 23% performed the test after 200 
administering 25 mg.   201 
With regards to imaging testing, CT-scan was the preferred test for 97% of the centers, 202 
whereas the remaining 3% considered magnetic resonance (MR) as the first imaging test to 203 
be performed after the confirmation of PA diagnosis. In subjects with PA, in the presence 204 
of adrenal nodule evaluated by imaging test, a dexamethasone overnight suppression test 205 
is always performed among 39% of the centers, performed only in the presence of large 206 
adrenal nodules (>1 cm) in 28% of the centers, and not routinely performed at the 33% of 207 
the centers unless a specific clinical suspicious of hypercortisolism is present. 208 
The evaluation of characteristics of circadian BP profile through automated blood pressure 209 
monitoring (ABPM) was requested by the vast majority of centers (90%). Conversely, 210 
screening for features of obstructive sleep apnea syndrome (OSAS) through validated 211 
questionnaires (e.g. Epworth Sleepiness Scale) in subjects screened for PA was habitually 212 
performed only by 29% of the centers. Genetic testing for familial forms of PA (long PCR 213 
for the chimeric CYP11B1/CYP11B2 gene and sequencing of the KCNJ5 gene) [18] are 214 
available in a small minority of the centres (27%). 215 
 216 
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Discussion 217 
The current article presents state-of-the-art results of laboratory and instrumental 218 
procedures and resources to perform a diagnosis of PA across Italian Hypertension 219 
Excellence and Reference centers endorsed by the SIIA. The two main findings of this survey 220 
are that there is large availability, among Italian centers, of laboratory and instrumental 221 
resources for screening and confirmation test for the diagnosis of PA. Conversely, some 222 
selected and cost-demanding procedures, which usually require dedicated staff and specific 223 
facilities, are available only in a limited proportion of the centers. The second evidence of 224 
the present survey is a rather heterogeneous behavior across centers in terms of 225 
methodologies and protocols related to diagnostic work-up for PA. 226 
According to guidelines, the diagnosis of PA is a three step process, comprising screening 227 
test, confirmatory testing and subtype diagnosis. Each of these steps could be variably 228 
affected by sub-optimal sensitivities and specificities, depending on a number of factors such 229 
as the characteristics of the population and the choice of cut-off points. A missed diagnosis 230 
of PA would result in an inappropriate exposure to increased CV risk, since PA is associated 231 
with a worse CV prognosis as compared to essential hypertension [Monticone S., 2018]. 232 
Moreover, insufficient detection and treatment of lateralized PA may be associated with a 233 
residual increased risk for cardiovascular events and mortality [Hundemer GL, 2018].  234 
Additionally, several studies pointed towards a reduced quality of life (QOL) in patients 235 
affected by PA compared with the general population [Veelema MS, JCEM 2018; Ahmed AH, 236 
JCEM 2011]. Specific PA treatment has been shown to improve QOL, with the unilateral 237 
adrenalectomy being more effective that MR antagonists [Veelema MS, JCEM 2018; Ahmed 238 
AH, JCEM 2011], underscoring once again the importance of diagnosing unilateral PA. 239 
The most reliable means to screen for PA is the ARR, which can be calculated using both 240 
the PRA and DRC in the denominator [18]. PRA has been traditionally measured by Radio-241 
Immuno-Assay , however DRC measurement with chemiluminescence assays (currently 242 
adopted in the 45% of the centers), which are fully automatized and do not produce 243 
radioactive waste,  is progressively replacing the traditional PRA in the evaluation of patients 244 
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affected by arterial hypertension.  Several studies showed that PRA and DRC display an 245 
overall good correlation, that becomes weaker for PRA values < 1 ng/mL/h, (Burrello J., 246 
2016; Dorrian C.A., 2010). The ES guideline [Funder JW, 2016] proposes a conversion factor 247 
of PRA (ng/mL/h) to DRC (mU/L) of 8.2. Applying this factor, an ARR of 30 (calculated with 248 
PRA measured in ng/mL/h) corresponds to an AARR (aldosterone to active renin ratio) of 249 
3.7 (calculated with the DRC measured in mU/L). However, three independent studies 250 
showed that the optimal sensitivity and specificity for the AARR are reached with significantly 251 
lower cut-offs (Burrello J., 2016; Rossi G.P., 2016; Manolopoulou J., 2015). According to 252 
these data, the use of a conversion factor between PRA and DRC should be discouraged 253 
and distinct cut-offs should be adopted for the ARR and the AARR. Several factors, including 254 
age, gender, time of day, serum K+ levels and, most importantly, antihypertensive 255 
medications, may affect ARR and should be taken into account [Funder JW, 2016]. 256 
According to ES guideline, it is mandatory to withdraw the most interfering medications, 257 
including K+ sparing and K+ wasting diuretics while the ARR can be confidently interpreted 258 
under the relatively noninterfering medications. Significant heterogeneity is expected for 259 
this step, reflecting clinicians’ preferences, the severity of hypertension and patients’ 260 
comorbidities. The practice of drug discontinuation (with the exception of alpha-blockers 261 
and calcium channel blockers), despite potentially associated with side effects [Fischer E, 262 
Rev Endocr Metab Disorder 2011], carries the lowest risk of false positive or false negative 263 
results and it is therefore the most frequently adopted strategy across the SIIA centers. 264 
Notably, the guidelines do not establish a precise cut-off for the ARR, which ideally should 265 
be tailored by each center according to the type of assay used and the Na+ intake of the 266 
population. The choice of a low cut-off to define a positive screening test (e.g. 20 with PAC 267 
in ng/dL and PRA in ng/mL/h or 2.4 with PAC in ng/dL and direct renin concentration in 268 
mU/L), as it is performed at the 4% of the centres, if on one hand maximizes sensitivity, on 269 
the other hand results in a high rate of false positives, thereby reducing the specificity and 270 
increasing time and costs associated with the performance of a confirmatory test. 271 
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Giving the high rate of false positive results of the ARR (57% in the PATO study), a 272 
confirmatory testing should always be performed to avoid patients with low renin essential 273 
hypertension to undergo costly and invasive diagnostic procedures such as adrenal CT 274 
scanning and AVS [18]. According to some authors [22], the FST is regarded as the gold-275 
standard test to definitively confirm or exclude PA diagnosis. However, it is costly and time 276 
consuming, and often requires the patient to be hospitalized for four days. For these reasons 277 
nowadays the SIT and the CCT, which represent valid alternatives to the cumbersome FST 278 
[23], are the most widely used ones. As expected, our results follow this trend, with the FST 279 
being available only in approximatively 1/3 of the centres. Surprisingly, also the possibility 280 
of performing a relatively simple confirmatory test is available only in 60% of the units in 281 
the case of SIT, and in 61% of the units in the case of CCT, indicating that a significant 282 
proportion of patients has to be referred to another centre. There is not an optimal protocol 283 
to perform the CCT test and two different doses (25 mg or 50 mg) of captopril can be 284 
administered. According to this survey, 50 mg is more frequently used dosage (in 77% of 285 
centres), but there is not enough evidence to prefer one protocol over the other. According 286 
to historical pharmacological studies, the main pharmacokinetic parameters after the 287 
administration of 25 mg or 50 mg of captopril were not significantly different (except for the 288 
area-under-the-curve standardized in relation to 1 mg of the dose) [24]: it is therefore 289 
conceivable that the administration of 25 mg or 50 mg of captopril will not significantly affect 290 
the performance of the test. 291 
As for the screening test, also for the SIT and the CCT test there is not general agreement 292 
on the best cut-off to define complete aldosterone suppression and definitively exclude PA 293 
diagnosis. While post SIT infusion PAC >10 ng/dL are generally deemed to be diagnostic of 294 
PA and a concentration <5 ng/dL indicative of a normal aldosterone suppression, values 295 
between 5 and 10 ng/dL represent a grey zone. We observed a wide heterogeneity across 296 
centres with respect to the cut-off chosen to define normal suppression after SIT: the 297 
answers were in fact almost equally distributed among the three options (5 ng/dL, 7.5 ng/dL 298 
and 10 ng/dL). Choosing a cut-off of 10 ng/dL maximizes the specificity and reduces the 299 
number of patients that have to be addresses to lateralization procedures; however, in a 300 
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recent study it has been shown that 29% of the patients with a post SIT PAC <5 ng/dL had 301 
a lateralized aldosterone production and were successfully cured by unilateral 302 
adrenalectomy [25]. The results of this study, methodologically sound and using strict 303 
criteria to define lateralized AVS, challenge the performance and the validity of SIT in 304 
definitively confirming or excluding PA diagnosis [25]. Therefore, some authors claim that 305 
prospective studies are warranted to establish if AVS indication should be extended to all 306 
patients with a positive screening test, in order to offer curative surgery to a greater number 307 
of PA patients (Cornu E., Hypertension 2016). 308 
After confirming the diagnosis, subtype testing should be performed in all PA patients who 309 
are candidate and desire surgical treatment by unilateral adrenalectomy. Subtype diagnosis 310 
comprises adrenal CT scanning (to rule out an aldosterone producing adrenal carcinoma) 311 
and the AVS to distinguish between unilateral and bilateral disease [18]. Despite significant 312 
advances in the optimization of the AVS procedure, with several issues having been 313 
addresed (Monticone S., Lancet DE 2015), it remains a poorly standardized procedure across 314 
centers (Kempers; Rossi). Different studies showed that adrenal imaging alone is not 315 
sensitive neither specific enough to define the source of aldosterone overproduction [26], 316 
notwithstanding the controversial SPARTACUS trial failed in demonstrating a superiority of 317 
AVS-based treatment over adrenal CT-scanning (Dekkers T., Lancet DE 2016; Beuschlein F, 318 
HMR 2017) in intensity of antihypertensive medication or clinical benefit. However, it must 319 
be acknowledged that the study was underpowered and the selected selection criteria did 320 
not allow to generalize the results to the overall PA population (Beuschlein F, HMR 2017).  321 
Whereas all hypertension centres should be encouraged to set up their own protocol and 322 
perform one or more confirmatory tests (which are safe and very often uncomplicated 323 
procedures) the “centralization” of AVS performance in few referral centers may be 324 
supported by the fact that an expert and dedicated radiologist is a key factor for increasing 325 
the successful cannulation of adrenal veins [Buffolo F., IJMS 2017] and a higher rate of 326 
adrenal vein rupture was observed in centres where a low number of procedures is 327 
performed [27]; by contrast this complication is rarely observed in centres with long 328 
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experience and high number of procedure per year [28]. In our cohort good AVS 329 
performance is achieved in the majority of the hypertension units; in centers with a low 330 
success rate, ACTH(1-24) infusion and measurement of serum cortisol during the procedure 331 
should be considered as useful strategies to improve successful cannulation of adrenal veins 332 
[Buffolo F., IJMS 2017]. 333 
A centralized approach would also be effective to improve the diagnosis of genetic forms of 334 
PA, such as familial hyperaldosteronism [29,30]. In fact, we observed that genetic testing 335 
is available only in a small minority of the hypertension specialist centers, suggesting that 336 
genetic forms of hyperaldosteronism could be currently underdiagnosed. 337 
We acknowledge that our results should be viewed in the lights of some limitations. Even 338 
whether the online survey could be conceived as a faster way of collecting data and 339 
increasing the response rate as compared to paper-and-pencil methods, some inherent 340 
disadvantages such as the absence of an interviewer, possible cooperator problems and 341 
potential dishonesty could negatively impact on results. In our survey we proposed 342 
anonymity to responders to reduce part of these limitations. As a consequence, those who 343 
did not respond to the survey could not be better characterized. 344 
In conclusion, a greater uniformity across centres to confirm/exclude PA is highly desirable, 345 
in order to guarantee the consistency of a diagnosis across the country. Creating a national 346 
consensus to define precise cut-offs for screening and confirmatory testing would be of 347 
great utility, in particular for those centres with low experience in the clinical management 348 
of patients with PA. However, this still could be largely hampered by the great heterogeneity 349 
of the assays used for aldosterone measurement, as mentioned previously. The promotion 350 
a national network between Italian hypertension specialist centers endorsed by the SIIA, in 351 
order to improve the awareness and spread the knowledge on PA screening and diagnosis, 352 
would be desirable also to facilitate the access to technically-demanding or costly 353 
procedures. 354 
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Figure legends 487 
 488 
Figure 1: cut-off value of aldosterone-to-renin ratio adopted by centers, suggesting the 489 
presence of PA. Reported values are related to ARR calculated from plasma aldosterone 490 
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concentration (ng/mL) and plasma renin activity (ng/mL/h)/ plasma aldosterone 491 
concentration (ng/mL) and direct renin concentration (mU/L) 492 
 493 
Figure 2: cut-off value of aldosterone-to-renin ratio adopted by centers, suggesting the 494 
presence of PA. Reported values are calculated from plasma renin activity, and 495 
correspond to 2.4, 3.7 and 4.9 ng/dL/mU/L if direct renin concentration is assessed 496 
 497 
  498 
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Tables 499 
 500 
 501 
 502 
Table 1: number of centers (and %) with availability of the related test and procedure 503 
for screening and diagnosis of PA, divided by macro-regions 504 
 
Total 
(n=62) 
North 
(n=30) 
Centre 
(n=15) 
South 
(n=17) 
Plasma renin activity 50 (81) 22 (73) 13  (87) 15 (88) 
Direct renin concentration 35 (56) 18 (60) 9 (60) 8  (47) 
Plasma aldosterone 62 (100) 30 (100) 15 (100) 17 (100) 
Urinary aldosterone 46 (74) 23 (77) 11 (73) 12 (71) 
Saline loading test 37 (60) 18 (60) 9 (60) 10 (59) 
Captopril challenge test 38 (61) 19 (63) 10 (67) 9 (53) 
Fludrocortisone 
suppression test 
20 (32) 11 (37) 4 (27) 5 (29) 
Adrenal vein sampling 20 (32) 10 (33) 6 (40) 4 (27) 
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